Amphastar Pharmaceuticals, Inc. (AMPH)
23.73
+0.77
(+3.35%)
USD |
NASDAQ |
Sep 02, 16:00
23.73
0.00 (0.00%)
After-Hours: 17:53
Amphastar Pharmaceuticals Research and Development Expense (TTM) : 79.43M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 79.43M |
| March 31, 2026 | 77.22M |
| December 31, 2025 | 71.24M |
| September 30, 2025 | 66.60M |
| June 30, 2025 | 65.68M |
| March 31, 2025 | 64.12M |
| December 31, 2024 | 61.43M |
| September 30, 2024 | 64.41M |
| June 30, 2024 | 60.83M |
| March 31, 2024 | 60.75M |
| December 31, 2023 | 63.89M |
| September 30, 2023 | 60.86M |
| June 30, 2023 | 62.69M |
| March 31, 2023 | 68.49M |
| December 31, 2022 | 64.71M |
| September 30, 2022 | 64.60M |
| June 30, 2022 | 56.78M |
| March 31, 2022 | 51.69M |
| December 31, 2021 | 49.92M |
| September 30, 2021 | 50.59M |
| June 30, 2021 | 57.43M |
| March 31, 2021 | 55.95M |
| December 31, 2020 | 57.08M |
| September 30, 2020 | 59.20M |
| June 30, 2020 | 60.58M |
| Date | Value |
|---|---|
| March 31, 2020 | 60.74M |
| December 31, 2019 | 60.26M |
| September 30, 2019 | 58.22M |
| June 30, 2019 | 51.83M |
| March 31, 2019 | 51.81M |
| December 31, 2018 | 51.83M |
| September 30, 2018 | 46.00M |
| June 30, 2018 | 44.90M |
| March 31, 2018 | 40.69M |
| December 31, 2017 | 38.36M |
| September 30, 2017 | 40.19M |
| June 30, 2017 | 39.79M |
| March 31, 2017 | 39.46M |
| December 31, 2016 | 36.46M |
| September 30, 2016 | 32.77M |
| June 30, 2016 | 34.45M |
| March 31, 2016 | 34.88M |
| December 31, 2015 | 33.27M |
| September 30, 2015 | 33.16M |
| June 30, 2015 | 31.52M |
| March 31, 2015 | 27.78M |
| December 31, 2014 | 27.71M |
| September 30, 2014 | 26.49M |
| June 30, 2014 | 26.95M |
| March 31, 2014 | 28.75M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Viatris, Inc. | 995.00M |
| Supernus Pharmaceuticals, Inc. | 124.20M |
| Liquidia Corp. | 54.95M |
| ANI Pharmaceuticals, Inc. | 49.91M |
| Corcept Therapeutics, Inc. | 253.86M |